Key clinical point: Intradermal delivery of etanercept could be a novel way to treat patients with discoid lupus erythematosus (DLE).
Major finding: More than half of patients (56%) achieved at least a 20% reduction in disease activity from baseline.
Study details: A phase 2, open-label, single-arm, “proof-of concept” study in 25 patients with DLE treated with etanercept.
Disclosures: The study was not commercially funded. Dr. Md Yusof had no disclosures. Pfizer provided the study drug free of charge.
Md Yusof MY et al. Rheumatology 2019;58(3):poster 244 doi: 10.1093/rheumatology/kez107.060.